Leading diabetes company plans deployment of IQVIA’s OCE technology
solution to transform engagement with healthcare professionals and to
improve the value of every client interaction
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA™ (NYSE:IQV) today announced that Novo Nordisk, a global healthcare
company with nearly a century of innovation and leadership in diabetes
care, has selected IQVIA’s market-leading Orchestrated Customer
Engagement platform for deployment across Novo Nordisk International
Operations.
IQVIA Technologies’ OCE for next-generation customer engagement
seamlessly connects marketing, sales, medical science liaisons, account
management and other functions to enhance the customer experience,
strengthen relationships and drive performance. IQVIA customers also
benefit from more accurate decision-making through predictive analytics,
machine learning and optimized performance. OCE is built on
best-in-class platforms, including Salesforce.com, MuleSoft, Amazon Web
Services, Heroku and Box.
Novo Nordisk plans to switch its existing platforms to OCE in 2019 and
beyond for this global rollout, excluding Canada and the U.S., enabling
them to streamline processes, further develop customer relationships and
better anticipate, and respond to market changes.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of
advanced analytics, technology solutions and contract research services
to the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding scope
of human science — to enable companies to reimagine and develop new
approaches to clinical development and commercialization, speed
innovation and accelerate improvements in healthcare outcomes. Powered
by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the
intersection of large-scale analytics, transformative technology and
extensive domain expertise, as well as execution capabilities. With more
than 55,000 employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps its customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers, and other healthcare stakeholders tap into
a deeper understanding of diseases, human behaviors, and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.iqvia.com.
About Novo Nordisk
Novo Nordisk is a global healthcare
company with 95 years of innovation and leadership in diabetes care.
This heritage has given us experience and capabilities that also enable
us to help people defeat obesity, haemophilia, growth disorders and
other serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 43,200 people in 79 countries and markets its
products in more than 170 countries. For more information, visit novonordisk.com,
Facebook,
Twitter,
LinkedIn,
YouTube.
IQVIAFIN
Click
here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181127005258/en/
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Source: IQVIA